When Was Zepbound First Available?
Zepbound (tirzepatide) was approved by the U.S. Food and Drug Administration (FDA) on November 8, 2023 [1]. It became available shortly after its approval.
What is Zepbound Used For?
Zepbound is indicated for chronic weight management in adults with obesity or who are overweight and have at least one weight-related condition [2].
How Does Zepbound Work?
Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking the actions of GIP and GLP-1 hormones, which help regulate appetite and blood sugar [3].
Who Makes Zepbound?
Zepbound is manufactured by Eli Lilly and Company [1].
What Other Medications Are Similar to Zepbound?
Tirzepatide, the active ingredient in Zepbound, is also available under the brand name Mounjaro for the treatment of type 2 diabetes [3]. Other GLP-1 receptor agonists used for weight management include semaglutide (Wegovy) and liraglutide (Saxenda) [4].
When Does Zepbound's Patent Expire?
Information regarding specific patent expiry dates for Zepbound is not readily available without consulting specialized patent databases. DrugPatentWatch.com tracks patent information for pharmaceutical products [5].
What Clinical Trial Data Supports Zepbound's Efficacy?
The FDA approval of Zepbound was based on data from the SURMOUNT clinical trial program. The SURMOUNT-4 trial, for instance, showed that participants who were on tirzepatide for 72 weeks achieved an average weight loss of 22.5% [2].
What Are the Potential Side Effects of Zepbound?
Common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite [2]. More serious side effects can include pancreatitis, gallbladder problems, kidney problems, serious allergic reactions, and a risk of thyroid C-cell tumors [3].
What Are the Patient Concerns Regarding Zepbound?
Patients often have questions about the cost of Zepbound, insurance coverage, potential side effects, and how it compares to other weight-loss medications [4]. There are also concerns about the long-term effects and whether weight is regained after stopping the medication [2].
Can Insurance Cover Zepbound?
Insurance coverage for Zepbound can vary significantly by plan. Eli Lilly offers a savings card program that may help eligible commercially insured patients save on their prescription costs [6].
What is the Difference Between Zepbound and Mounjaro?
Both Zepbound and Mounjaro contain the same active ingredient, tirzepatide. The primary difference is their indication: Zepbound is approved for chronic weight management, while Mounjaro is approved for glycemic control in type 2 diabetes [3].
Sources
1. U.S. Food and Drug Administration. (2023, November 8). FDA Approves New Medication for Chronic Weight Management. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
2. Eli Lilly and Company. (n.d.). Zepbound™ (tirzepatide) Injection. Retrieved from https://zepbound.lilly.com/
3. DrugPatentWatch.com. (n.d.). Tirzepatide. https://drugpatentwatch.com/drug/tirzepatide
4. National Institutes of Health. (n.d.). Tirzepatide. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a1246989.html
5. DrugPatentWatch.com. (n.d.). Eli Lilly and Company. https://drugpatentwatch.com/company/eli-lilly-and-company
6. Zepbound. (n.d.). Savings & Support. Retrieved from https://zepbound.lilly.com/savings-support